KOSDAQ foreign investors’ 2.5 trillion-won buying spree, focused on biotech and semiconductors
Foreign investors 5 in 22 on the KOSDAQ net bought 2.5 trillion won, while shares of D&D Pharmatech and GI Innovation surged on positive biotech clinical-trial news. Ingenia Therapeutics received approval for its preliminary listing review.
Foreign investors 2026-05-22 net bought 2.5 trillion won, mainly on the KOSDAQ. Buying was concentrated in the semiconductor, robotics and biotech sectors. Trading that day saw a strong reaction to individual biotech clinical-trial announcements.
A company that manufactures active pharmaceutical ingredients 2026-05-23 disclosed the effects of expanding its plant. The company said that orders had increased and performance had improved following the expansion. It explained that supply volumes and shipments had expanded.
D&D Pharmatech 2026-05-22 saw its share price rise 14% on expectations for clinical data related to the European liver congress. The company reported increased investor interest, citing the abstract it submitted to the congress. Trading continued to focus on the clinical results in question.
GI Innovation’s share price 23% after the ASCO abstracts were released. The company said it reported an ORR of 40% in a kidney cancer clinical trial of its immuno-oncology drug. The company presented plans for further research based on the data.
Korean-American biotech company Ingenia Therapeutics received approval for its preliminary listing review. The company disclosed that it would step up preparations for its listing. Approval of the preliminary review is part of the initial public offering process.
The market’s direction that day reflected both net buying by foreign investors and individual biotech clinical trial announcements. Volatility appeared to increase among biotech and technology stocks on the KOSDAQ. Investors and institutions traded while taking both clinical results and changes in supply and demand into account.